As expansive as we are from a more general standpoint, we humans suffer from our fair share of limitations. These limitations mirror our own versatility, thus dealing with them at times becomes a real challenge. Nevertheless, we still continue to try and find solutions, which are entirely purposed around widening the pool of all what we can do. Over the years, our efforts in this regard have delivered substantial dividends, and what makes it even better is the fact that the said dividends happen to be somewhat evenly spread across different areas in our lives. As you can guess, such a scenario aims directly for more collective growth, and the benefits of it are around us in spades. Now, even though every such attempt has made a unique impact on our lives, when you look at something like technology, it just easily takes over the party. In a world where human beings are constantly trying to become better, having a tool of technology’s caliber has unsurprisingly ended up playing a big role to help our push. To assess the creation’s work on a granular level, we can take a look at how it transformed our surroundings before eventually transforming us as a society. One channel through which technology achieved the said objective was of healthcare. The healthcare sector has always been an essential area of our lives, but with its structure crumbling, the sphere needed a rebuild. Technology gave it that and much more by introducing a brand of medtech. Driven by many forces, the medtech concept has literally altered our perception about the global healthcare landscape, and yet its progressive nature hasn’t stopped thriving for a second. In the sector’s latest bid to shake things up, we’ll be witnessing one of its most important branches taking a big step forward.
BioMarin Pharmaceuticals, a leading name in the pharmaceuticals industry, has bagged FDA approval for the company’s new drug, Voxzogo, which can be used to treat achnodroplasia. If you are not quite aware, achnodroplasia is an inherited disorder responsible for the most common form of dwarfism. Being the first ever FDA-approved drug that focuses on this condition, Voxzogo will cover children who are 5 years old or older and still have open growth plates. The regulatory nod comes after a highly successful Phase-3 study that saw participation of over 121 children in total. According to some reports, the children given Voxzogo drug grew an average of 1.57 centimeters taller than the ones given placebo.
BioMarin expects the drug to become its highest-selling product so far, beating Vimzim, the company’s enzyme replacement therapy that brought over $544.4 million in sales last year.
“What I believe is Voxzogo has the biggest long term revenue potential, relative to the products that have been approved before it, including Vimizim, which is our largest marketed product to date,” said Jeff Ajer, Chief Commercial Officer of BioMarin.
While BioMarin certainly has a headstart within the established context, other pharmaceutical companies aren’t a long way behind. The likes of Pfizer, Ascendis Pharma, and Tyra Biosciences are working around the clock to make similar forays soon.
